TScan Therapeutics, Inc.
TCRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $340 | $382 | $37 | $108 |
| - Cash | $179 | $133 | $120 | $161 |
| + Debt | $97 | $92 | $86 | $6 |
| Enterprise Value | $259 | $342 | $3 | -$48 |
| Revenue | $3 | $21 | $14 | $10 |
| % Growth | -86.6% | 55.5% | 33.5% | – |
| Gross Profit | $3 | $21 | $14 | $10 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$120 | -$80 | -$60 | -$45 |
| % Margin | -4,252.1% | -380.5% | -442.6% | -446.7% |
| Net Income | -$127 | -$89 | -$66 | -$49 |
| % Margin | -4,527.7% | -423.9% | -489.3% | -479.5% |
| EPS Diluted | -1.14 | -1.36 | -2.74 | -2.03 |
| % Growth | 16.2% | 50.4% | -35% | – |
| Operating Cash Flow | -$111 | -$61 | -$67 | -$49 |
| Capital Expenditures | -$4 | -$3 | -$4 | -$10 |
| Free Cash Flow | -$115 | -$65 | -$71 | -$59 |